ACT: Colchicine and aspirin in community patients with COVID-19: an open-label, factorial, randomised, controlled trial

Lancet Respiratory Medicine

JW Eikelboom, SS Jolly, EP Belley-Cote, RP Whitlock, S Rangarajan, L Xu, L Heenan, SI Bangdiwala, WM Tarhuni, M Hassany, A Kontsevaya, W Harper, SK Sharma, P Lopez-Jaramillo, AL Dans, LM Palileo-Villanueva, A Avezum, P Pais, D Xavier, C Felix, A Yusufali, RD Lopes, O Berwanger, Z Ali, S Wasserman, SS Anand, J Bosch, S Choudhri, ME Farkouh, M Loeb, S Yusuf

October 2022

Read More

ACT: Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19: an open-label, factorial, randomised, controlled trial

Lancet Respiratory Medicine

J Eikelboom, SS Jolly, EP Belley-Cote, RP Whitlock, S Rangarajan, L Xu, L Heenan, SI Bangdiwala, ML Diaz, R Diaz, A Yusufali, SK Sharma, WM Tarhuni, M Hassany, A Avezum, W Harper, S Wasserman, A Almas, O Drapkina, C Felix, RD Lopes, O Berwanger, P Lopez-Jaramillo, SS Anand, J Bosch, S Choudhri, S Choudhri, ME Farkouh, M Loeb, S Yusuf

October 2022

Read More

COMPLETE: Complete revascularization vs culprit lesion–only percutaneous coronary intervention for angina-related quality of life in patients with ST-segment elevation myocardial infarction

JAMA Cardiology

SR Mehta, J Wang, DA Wood, JA Spertus, DJ Cohen, R Mehran, RF Storey, PG Steg, N Pinilla-Echeverri, T Sheth, KR Bainey, S Bangalore, WJ Cantor, DP Faxon, LJ Feldman, SS Jolly, V Kunadian, S Lavi, J Lopez-Sendon, M Madan, R Moreno, SV Rao, J Rodes-Cabau, G Stankovic, SI Bangdiwala, JA Cairns

September 2022

Read More

PURE: Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis

The Lancet

M Walli-Attaei, A Rosengren, S Rangarajan, Y Breet, S Abdul-Razak, W Al Sharief, KF Alhabib, A Avezum, J Chifamba, R Diaz, R Gupta, B Hu, R Iqbal, R Ismail, R Kelishadi, R Khatib, X Lang, S Li, P Lopez-Jaramillo, V Mohan, A Oguz, LM Palileo-Villanueva, K Poltyn-Zaradna, PR Sreelakshmi, LVM Pinnaka, P Seron, K Teo, ST Verghese, A Wielgosz, K Yeates, R Yusuf, SS Anand, S Yusuf

September 2022

Read More

PACIFIC-Stroke: Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke – an international, randomised, double-blind, placebo-controlled, phase 2b trial

The Lancet

A Shoamanesh, H Mundi, EE Smith, J Masjuan, I Milanov, T Hirano, A Agafina, B Campbell, V Caso, JL Mas, Dong, P Turcani, H Christensen, JM Ferro, R Veltkamp, R Mikulik, GM De Marchis, T Robinson, R Lemmens, A Stepien, S Greisenegger, R Roine, L Csiba, P Khatri, J Coutinho, AG Lindgren, AM Demchuk, P Colorado, B Kirsch, C Neumann, L Heenan, L Xu, SJ Connolly, RG Hart

September 2022

Read More

INVICTUS: Rivaroxaban in rheumatic heart disease–associated atrial fibrillation

The New England Journal of Medicine (NEJM)

SJ Connolly, G Karthikeyan, M Ntsekhe, A Haileamlak, A El Sayed, A El Ghamrawy, A Damasceno, A Avezum, AML Dans, B Gitura, D Hu, ER Kamanzi, F Maklady, G Fana, JA Gonzalez-Hermosillo, J Musuku, K Kazmi, L Zuhlke, L Gondwe, C Ma, M Paniagua, OS Ogah, OJ Molef-Baikai, P Lwabi, P Chillo, SK Sharma, TTJ Cabral, WM Tarhuni, A Benz, M van Eikels, A Krol, D Pattath, K Balasubramanian, S Rangarajan, C Ramasundarahettige, B Mayosi, S Yusuf

August 2022

Read More

Back To Top